We are live on ! Find out more
LPCN icon

Lipocine

58 hedge funds and large institutions have $30.3M invested in Lipocine in 2016 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 12 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

367% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 3

33% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 12

23% more funds holding

Funds holding: 4758 (+11)

2.65% more ownership

Funds ownership: 0%2.65% (+2.7%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

17% less capital invested

Capital invested by funds: $36.5M → $30.3M (-$6.18M)

Holders
58
Holders Change
+11
Holders Change %
+23.4%
% of All Funds
1.45%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
14
Increased
16
Reduced
12
Closed
3
Calls
$160K
Puts
Net Calls
+$160K
Net Calls Change
+$216K

LPCN Hedge Fund Activity: Q4 2016 in Review

58 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2016, worth a combined $30.3M — down 17% from $36.5M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new LPCN positions and 3 closed out — a net gain of 11 holders — while 16 added to existing stakes and 12 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $697K. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $1.35M sold.

  • 58 institutional investors held Lipocine (LPCN) as of Q4 2016, up from 47 in Q3 2016.
  • Funds reported $30.3M of Lipocine stock for Q4 2016, down 17% quarter-over-quarter.
  • 14 funds opened new Lipocine positions in Q4 2016 and 3 closed out, a net change of +11 holders.
  • The largest Lipocine buyer in Q4 2016 was Millennium Management, an estimated $697K added.
  • The largest Lipocine seller in Q4 2016 was Foresite Capital Management III, an estimated $1.35M sold.

Based on aggregated 13F filings for Q4 2016.